Στείλτε το σ' έναν φίλο
RSS
google +
Εκτύπωση

Νέα (Παράνομες ουσίες)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

Click and learn with the new-look Best practice portal from the European Monitoring Centre for Drugs and Drug Addiction    europa.eu

Targeted at practitioners and professionals, the portal is designed as a practical and reliable source of what works, and what doesn’t, in the areas of drug-related prevention, treatment, harm reduct[...]

Dopaminergic agents and nutritional status in Parkinson's disease    epda.eu.com

Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only[...]

The dopaminergic system in upper limb motor blocks (ULMB) investigated during bimanual coordination in Parkinson's disease (PD)    epda.eu.com

The current study investigated the occurrence of ULMB in PD participants without ('off') and with ('on') dopamine replacement using bimanual wrist flexionextension with external auditory cues.[...]

Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease    epda.eu.com

Study findings support the hypothesis that nigrostriatal dopaminergic deficit is associated with executive impairment, but not to memory or visuospatial impairment, in early PD.[...]

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial    epda.eu.com

Study findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives a[...]

Dopaminergic medication does not improve stepping responses following backward & forward balance perturbations in Parkinson's    epda.eu.com

In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.[...]

Puerarin protects dopaminergic neurons in Parkinson's disease models    epda.eu.com

These data indicated that puerarin alleviated the oxidative stress and apoptosis in a PD cellular model, protected the dopaminergic neurons against rotenone toxicity and decreased the abnormal protei[...]

Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect    epda.eu.com

Results: Mortality rate was 56.8%. Although higher age (p 0.48).[...]

Dopaminergic agents and nutritional status in Parkinson's disease    epda.eu.com

Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only[...]

Just published: EMCDDA-Europol 2013    europa.eu

This report presents the key activities performed by the EMCDDA and Europol in 2013, with details on all the relevant activities in support of the implementation of Council Decision 2005/387/JHA on t[...]

EMCDDA releases state-of-the-art review on drugs and driving    europa.eu

The EMCDDA releases a state-of-the-art review on drugs and driving today ahead of International day against drug abuse and illicit trafficking.[...]

EU drugs agency places six topics in the spotlight with new online analyses    europa.eu

The EU drugs agency (EMCDDA) releases today alongside its European Drug Report 2014: Trends and developments, six new additions to its Perspectives on drugs (PODs) series. This latest selection of on[...]

Largest multi-city study on drug wastewater analysis released today    europa.eu

The findings of the largest European project to date in the emerging science of wastewater analysis (WWA) are released today in an article published in Addiction. The project in question - steered by[...]

Just published: European Drug Report 2014: Trends and developments    europa.eu

How many new drugs were detected in Europe over the last year? Is cannabis getting stronger? How many Europeans have ever used an illicit drug? What are the latest drug policy developments in the reg[...]

Just published: Risk assessment of methoxetamine    europa.eu

This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone, that was conducted by the Scientific Committee of[...]

Just published: Risk assessment of AH-7921    europa.eu

This report presents the data and findings of the risk assessment on the new psychoactive substance, 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide, that was conducted by the Scientifi[...]

Just published: Risk assessment of MDPV    europa.eu

This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one, that was conducted by the Scientific Com[...]

Just published: Risk assessment of 25I-NBOMe    europa.eu

This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, that was conducted by the Scientific[...]

Disclaimer

The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.